Oral Solid Dosage Pharmaceutical Formulation Market is expected to reach US$ 1.0 Billion by 2032

 Demand for the global oral solid dosage pharmaceutical formulation market is anticipated to expand at a robust CAGR of 6.4% over the valuation period from 2022 to 2032. The global market is expected to touch US$ 555.3 Million by 2022 and surpass a valuation of US$ 1.0 Billion in 2032. As per the studies, on the basis of dosage, the tablets segment led to the market with a massive share of around 53.1% in 2021.

As per Future Market Insights analysis, the oral solid dosage pharmaceutical formulation market accounted for around 1.4% of the overall US$ 40.0 Billion of the global pharmaceutical drug delivery market in 2021. The expansion of sales of solid dosage pharmaceutical formulations was anticipated at a robust rate of 8.1% from 2012 to 2021, attributed to the surging adoption and greater patient compliance.

Get Full Access @ https://www.futuremarketinsights.com/reports/oral-solid-dosage-pharmaceutical-formulation-market

Oral solid dosages are one of the most commonly utilized pharmaceuticals that help in treating multiple chronic diseases. These oral solid dosages are witnessing high sales due to their cost-effective nature and are easily available in retail and hospital pharmacies across the globe. These dosage forms are easily manufactured and come with an affordable price point in numerous underdeveloped nations. This is expected to create lucrative growth prospects for the key players.

Key Takeaways

  • Since several research institutions and organizations are engaged in the drug discovery process, there is a massive amount of oral solid drugs in the process of approval with improved efficacy. Once these products are approved, the manufacturers are expected to be benefitted from generating profitable sales. Therefore, a positive impact due to the surging number of drug pipelines can be witnessed in the oral solid dosage pharmaceutical formulation market during the forecast period.
  • There is an overall surge witnessed in the demand for oral solid dosage drugs and vaccines for the treatment of various diseases and infections has also increased worldwide. Hence, prominent players in the market are working on developing drug manufacturing capacities of their own in low and medium-economy regions to capitalize on low production costs and availability of cost-effective raw materials.
  • Various firms practice the primary process of oral solid dosage pharmaceutical formulation. This is because the solid form of the drug is known to be the easiest and simplest way of administering a drug in order to have just the appropriate dose for various acute and chronic infections.

  • Such dosage forms offer advantages including chemical durability, stable transport, and safe packaging with low production costs. On the basis of region, Asia Pacific is expected to dominate the growth in the oral solid dosage pharmaceutical formulation market.
  • Tablets and capsules are utilized in pharmaceuticals to efficiently treat several disease conditions. In comparison to other pharmacological forms, these are cost-efficient and easy to manufacture. They offer several advantages such as easy transport and packaging and superior chemical and physical stability. Dominant market players are partnering with small and medium-sized manufacturers to produce low-cost and top-notch generic drugs maintained at a low cost of production in developing nations.

Competitive Landscape

  • AstraZeneca Plc.
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • Gilead Sciences
  • Merck & Co. Inc
  • Novartis AG
  • Pfizer Inc.
  • AbbVie Inc.
  • Boehringer Ingelheim GmbH
  • F. Hoffman-La-Roche Ltd.
  • Johnson & Johnson
  • Biogen Inc.
  • Bayer AG
  • Teva Pharmaceuticals
  • Amgen Inc.
  • Takeda Pharmaceutical Company Ltd.
  • Otsuka Pharmaceutical Co., Ltd.
  • Shire Plc.
  • Celgene Corporation
  • Astellas Pharma Inc.

Key Market Segments Covered in Oral Solid Dosage Pharmaceutical Formulation Market Research

By Dosage Form:

  • Tablets
    • Conventional/Immediate Release
    • Modified Release
    • Chewable Tablets
    • Effervescent Tablets
  • Capsules
    • Hard Gelatin Capsules
    • Soft Gelatin Capsules
    • Others
  • Powders & Granules
  • Lozenges & Pastilles
  • Gummies

By Drug Release Mechanism:

  • Immediate Release
  • Delayed Release
  • Controlled Release

By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Drug Stores
  • Online Pharmacies
  • Hypermarkets/Supermarkets

Comments

Post a Comment

Popular posts from this blog

Monoclonal Antibodies Market to touch US$ 647.01 Billion by 2032; applications abound in Oncology | FMI Report

Image
  Monoclonal Antibodies Market is projected to increase at a CAGR of 12% during the forecast period between 2022 and 2032, reaching a total of US$ 647.01 Billion in 2032, according to a report from Future Market Insights (FMI). From 2017 to 2021, sales witnessed significant growth, registering a CAGR of 6.1%. Human mAbs offer efficient modulation in effector functions and are less immunogenic as compared to chimeric or humanized mAbs. Such antibodies can be produced through the use of phage display and hybridoma technologies in transgenic mice. As a result, with recent technological progress in genetic engineering, the production of fully human mAbs is anticipated to gain traction in the near future.  Get Full Access @ https://www.futuremarketinsights.com/reports/monoclonal-antibodies-market North America recorded the largest market share of 46.2% in 2021 due to the presence of a highly developed healthcare infrastructure, high patient awareness, and growth in cancer research pr
Read more

Companion Diagnostics Market Recent Trends, Dynamic Innovation in Technology & Insights 2032

Image
  The global Companion Diagnostics Market is expected to generate approximately US$ 5152.064939 million by 2032, up from US$ 2452.653722 million in 2022, at a CAGR of 7.1% during the forecast period. With the latest insights and statistics from the biggest pharmaceutical and healthcare device manufacturers across the globe, FMI presents an extensive analysis on Companion Diagnostics market. To read more about this report, visit @ https://www.futuremarketinsights.com/reports/companion-diagnostics-market FMI offers insights into the market data on over 5000+ drugs for more than 100 countries, which further aids the research on current and upcoming market scenario for the Companion Diagnostics market. Our expert researchers and analysts for healthcare tracks the data of established players as well as new entrants in medical industry to provide an unbiased analysis for a sound and financial decision. Over the past decade, healthcare sector has been expanding remarkably, followi
Read more

Hospital Consumables Market is expected to reach valuation of US$ 853.2 Billion | FMI

  According to Future Market Insights' newly released Hospital Consumables market analysis report, global Hospital Consumables market sales in 2021 are expected to be US$ 346 billion. The estimated market growth of 12.5% between 2022 and 2032 is expected to be much greater than the previous trend. The consumables market is estimated to have a total revenue opportunity of US$ 853.2 billion. The increase in chronic diseases, medical operations, and the expanding older population are driving market expansion. To learn more about this report @ https://www.futuremarketinsights.com/reports/hospital-consumables-market With the latest insights and statistics from the biggest pharmaceutical and healthcare device manufacturers across the globe, FMI presents an extensive analysis on Hospital Consumables market. FMI offers insights into the market data on over 5000+ drugs for more than 100 countries, which further aids the research on current and upcoming market scenario for the Hospita
Read more